GlassScriptPhysician profile
Karuna Kusan
NPI 1013921329
$6,580.47
in general payments reported to CMS, 2019-2025
27 companies · $1,017 in 2025
The $1,017 reported for 2025 was more than what 79% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $473 · 2020: $521 · 2021: $934 · 2022: $1,104 · 2023: $1,209 · 2024: $1,323 · 2025: $1,017.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,520 · Education: $28.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,519.62 |
| Education | $28.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $1,299.94 | 2019-2025 | Dovato, Cabenuva, Rukobia |
| Gilead Sciences, INC. | $970.18 | 2020-2025 | |
| Merck Sharp & Dohme LLC | $814.53 | 2019-2025 | Zerbaxa, Delstrigo, Pifeltro |
| Melinta Therapeutics, LLC | $792.98 | 2019-2025 | Orbactiv, Kimyrsa, Rezzayo |
| Paratek Pharmaceuticals, INC. | $524.69 | 2021-2025 | Nuzyra |
| Insmed, INC. | $473.00 | 2019-2025 | Arikayce, Brinsupri |
| Abbvie INC. | $350.09 | 2019-2025 | |
| Janssen Biotech, INC. | $326.86 | 2019-2023 | Symtuza |
| La Jolla Pharmaceutical Company | $228.31 | 2021-2025 | Xerava, Zevtera |
| Cumberland Pharmaceuticals, INC. | $110.85 | 2024-2025 | Vibativ |
| Takeda Pharmaceuticals U.S.A., INC. | $75.00 | 2021-2024 | Hyqvia |
| Theratechnologies INC. | $71.11 | 2019-2023 | Egrifta, Trogarzo |
| Grifols USA, LLC | $63.15 | 2022-2025 | Gamunex-C, Xembify |
| Ferring Pharmaceuticals INC. | $61.50 | 2024-2025 | Rebyota |
| Janssen Pharmaceuticals, INC | $56.96 | 2021-2023 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shionogi INC | $52.41 | 2023 | Fetroja |
| Astellas Pharma US INC | $50.64 | 2024 | Cresemba |
| Angiodynamics, INC. | $46.25 | 2025 | Angiovac |
| Organogenesis INC. | $42.46 | 2024 | |
| Janssen Products, LP | $31.49 | 2021 | |
| Allergan, INC. | $28.25 | 2019-2020 | |
| Napo Pharmaceuticals INC | $23.41 | 2025 | Mytesi |
| Mayne Pharma Commercial LLC | $20.25 | 2021 | |
| Pfizer INC. | $18.53 | 2022 | |
| Tetraphase Pharmaceuticals, INC. | $16.43 | 2025 | |
| Nabriva Therapeutics, Plc | $16.34 | 2020 | |
| Argentum Medical | $14.86 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karuna Kusan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.